Supernus Pharmaceuticals Inc
|Market Cap (Intraday)||1.49B|
|2yr Forward PE||19.69|
Supernus Pharmaceuticals Inc Stock, NASDAQ:SUPN
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.